BREAKING NEWS
This content is not available in your region

ImmuPharma licenses lupus drug Lupuzor to Avion in the United States

Access to the comments Comments
Text size Aa Aa

LONDON (Reuters) – British pharmaceutical firm ImmuPharma <IMM.L> said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals.

Avion and ImmuPharma will co-develop Lupuzor, including a new Phase III trail, and Avion will commercialise the drug exclusively in the United States, ImmuPharma said.

The British company said it would receive milestone payments of up to $70 million, comprising $5 million upon regulatory approval and up to $65 million based on sales targets.

(Reporting by Paul Sandle; editing by Kate Holton)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.